Published • loading... • Updated
Eli Lilly Raises Annual Revenue Forecast as GLP-1 Drugs Fuel Growth
Mounjaro and Zepbound generated nearly $15 billion in quarterly sales as worldwide volume rose 60%, helping Lilly lift full-year revenue guidance.
- On Wednesday, Eli Lilly reported second-quarter revenue surged 48% to $23 billion, cementing its status as the only pharmaceutical company trading above a $1 trillion market cap.
- Booming demand for the company's GLP-1 drugs drove these results, with Mounjaro sales surging 91% to $9.9 billion and Zepbound sales rising 46% to $4.9 billion.
- Encouraged by sustained sales momentum, Lilly raised full-year revenue guidance to between $85 billion and $87 billion, up from the prior range of $82 billion to $85 billion.
- Strengthening its future pipeline, the drugmaker committed an additional $4.5 billion to Indiana manufacturing and plans a first-quarter 2027 BLA filing for retatrutide.
- While worldwide volume grew 60% despite a 13% decline in realized prices, analysts remain bullish on Lilly's ability to convert its pipeline into additional blockbusters.
Insights by Ground AI
11 Articles
11 Articles
State accuses Wildwood pharmacist of illegally dispensing weight loss drug - Villages-News.com
The Florida Department of Health has filed an administrative complaint against a Wildwood pharmacist, alleging he illegally dispensed the popular weight-loss medication Wegovy under a doctor’s name without the physician’s knowledge or authorization. Read more: State accuses Wildwood pharmacist of illegally dispensing weight loss drug
·Lady Lake, United States
Read Full Article
Eli Lilly’s Weight-Loss Drug Demand Is Nearly Limitless. Here’s What Comes Next for the $1 Trillion Drugmaker
Eli Lilly just posted numbers that stunned Wall Street, but the company's own executives admit a single bottleneck could cap how far the GLP-1 juggernaut actually runs, and the next move to break through it is already in motion.
·Lakewood, United States
Read Full Article
Coverage Details
Total News Sources11
Leaning Left1Leaning Right2Center5Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
13%
C 62%
R 25%
Factuality
To view factuality data please Upgrade to Premium
